Articles tagged "Immunosuppression"

2018 American Transplant Congress
Patients Converted to Belatacept Show Different Immunophenotyping Compared with De Novo Belatacept-Treated Patients
M. Rial,¹ F. Caro,² A. Nella,² D. Guerrieri,² L. León,¹ P. Uva,¹ E. Chuluyan,² D. Casadei.¹
¹Instituto de Nefrología, Nephrology, Buenos Aires, Argentina; ²CEFYBO, UBA, CONICET, Buenos Aires, Argentina.
The incidence of adverse clinical events mainly in early, but not late post-transplantation such as an increased rate of acute rejection precludes the use of…
2018 American Transplant Congress
Effect of Everolimus on Body Composition; 1-Year after Kidney Transplantation
M. Yoshikawa,¹ T. Ishimura,² S. Nishi.¹
¹Division of Nephrology, Kobe University Graduate School of Medicine, Kobe, Japan; ²Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
【Background】Weight gain, and especially visceral fat gain early after kidney transplantation has a worse outcome for metabolic disorder, graft function, and cardiovascular disease. The mammalian…
2018 American Transplant Congress
Human CD8⁺CD28^– T Cells Driven In Vitro by IL-15 Suppress in Allo-Specific Manner Partially through PD-1:PD-L1 Pathway
F. Feng,^1,2 G. Liu,¹ P. Zhu,¹ M. Zhu,¹ X. Lu,¹ J. Liu,² X. Luo,³ Y. Liu,¹ Y. Yu.²
¹Department of Immunology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China; ²Department of Urology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China; ³Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: CD8+CD28- T suppressor cells (Ts) have emerged as an important modulator of alloimmunity, but the in vitro inducibility of Ts subsets is rather unclear.…
2018 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in De Novo Living Kidney Transplantation Patients: A Multicenter, Parallel Group, Open-Label, 5-Year Randomized Noninferiority Trial
Y. Kakuta,¹ M. Okumi,¹ K. Unagami,² M. Furusawa,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
BackgroundTacrolimus is available as twice-daily (TAC-BID) and once-daily (TAC-QD) formulations. Findings from pharmacokinetic and short-term trials are available. However, results from long-term trials are limited.We…
2018 American Transplant Congress
Maintenance Immunosuppression Trends in Hand and Facial VCA Transplantation
A. Manjunath,¹ M. Cammarata,¹ R. Kantar,¹ W. Rifkin,¹ A. Jacoby,¹ B. Gelb,² R. Diaz-Siso,¹ E. Rodriguez.¹
¹Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY; ²Transplant Institute, NYU Langone Health, New York, NY.
PURPOSE: Authors have speculated that vascularized composite allotransplantation recipients (VCAR) require greater maintenance immunosuppression than solid organ recipients due to skin's higher antigenicity. This has…
2018 American Transplant Congress
Influence of Trough Level in Tacrolimus on the Appearance Rate of De Novo Donor Specific Antibody (dnDSA) under Low Dose-Based Tacrolimus Protocol during 7 Years Follow-Up after Renal Transplantation
H. Ishida,¹ K. Tanabe,² T. Shimizu,¹ M. Furusawa.²
¹Organ Transplantation Medicine, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background. Tacrolimus low trough protocol has been adopted at our institution since 2000.The purpose in this study is to investigate the relationship between maintenance trough…
2018 American Transplant Congress
Transplant Cost Reduction in a Developing Country: “The Case of Guatemala”
S. Méndez,¹ B. Remey,² E. Reyes,¹ A. Aguilar-González,¹ R. Lou-Meda.¹
¹Servicio de Nefrología, Hipertensión, Diálisis y Trasplante Hospital Roosevelt/FUNDANIER, Guatemala, Guatemala; ²Department of Pharmaceutical Chemistry, Universidad del Valle de Guatemala, Guatemala, Guatemala.
Background: Guatemala, south-west of Mexico has a population of approximately 16 million people of which 60% are younger than 20 years. As any other developing…
2018 American Transplant Congress
Single Center Experience of HLA-Related Donor Specific Antibody in Living Donor Liver Transplantation
H. Egawa,¹ Y. Kotera,¹ A. Ohmori,¹ S. Yamashita,¹ T. Kato,¹ S. Nemoto,¹ T. Ishizuka,² M. Yamamoto.¹
¹Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Clinical Laboratory, Tokyo Women's Medical University, Tokyo, Japan.
Although impact of donor specific antibody in liver transplantation has been recognized, significance of desensitization is not established yet. Our aim is to share our…
2018 American Transplant Congress
Multi-Targeting Desensitization Therapy Alters Peripheral B-Cell Homeostasis and Suppresses Recall Alloantibody Responses
I. Kim, G. Wu, N-.N. Chai, A. Klein, S. Jordan.
CTC/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Purpose: Occurring of donor specific antibodies (DSA) is injurious to organ transplant. Development of immunotherapies to suppress DSA, therefore, has been one of the strategic…
2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
J. Gottlieb, C. Neurohr, J. Müller-Quernheim, H. Wirtz, B. Sill, H. Wilkens, V. Besa, C. Knosalla, M. Junge, C. Capusan, M. Strüber.
Klinik, Hannover, Germany; Klinik, München, Germany; Klinik, Freiburg, Germany; Klinik, Leipzig, Germany; Klinik, Hamburg, Germany; Klinik, Homburg, Germany; Klinik, Essen, Germany; Klinik, Berlin, Germany; Novartis Pharma, Nürnberg, Germany; Novartis Pharma, Nürnberg, Germany; Klinik, Hannover, Germany.
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…